Do we need to apply a T2T strategy even in ACPA-negative early rheumatoid arthritis? YES

Documenti analoghi

• Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?
  di: Ferraccioli, Gianfranco, et al.
  Pubblicazione: (2016)
• Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis
  di: Alivernini, Stefano, et al.
  Pubblicazione: (2019)
• Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression
  di: Bosello, Silvia, et al.
  Pubblicazione: (2011)
• Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission
  di: Alivernini, Stefano, et al.
  Pubblicazione: (2016)
• Memory B cell subsets and plasmablasts are lower in early than in long-standing Rheumatoid Arthritis
  di: Fedele, Anna Laura, et al.
  Pubblicazione: (2014)